Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study.
Cilloni D, Ravera S, Calabrese C, Gaidano V, Niscola P, Balleari E, Gallo D, Petiti J, Signorino E, Rosso V, Panuzzo C, Sabatini F, Andreani G, Dragani M, Finelli C, Poloni A, Crugnola M, Voso MT, Fenu S, Pelizzari A, Santini V, Saglio G, Podestà M, Frassoni F. Cilloni D, et al. Among authors: fenu s. Sci Rep. 2020 Jun 8;10(1):9156. doi: 10.1038/s41598-020-66162-y. Sci Rep. 2020. PMID: 32514107 Free PMC article.
Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy.
Efficace F, Santini V, La Nasa G, Cottone F, Finelli C, Borin L, Quaresmini G, Di Tucci AA, Volpe A, Cilloni D, Quarta G, Sanpaolo G, Rivellini F, Salvi F, Molteni A, Voso MT, Alimena G, Fenu S, Mandelli F, Angelucci E. Efficace F, et al. Among authors: fenu s. BMJ Support Palliat Care. 2016 Mar;6(1):80-8. doi: 10.1136/bmjspcare-2014-000726. Epub 2014 Sep 9. BMJ Support Palliat Care. 2016. PMID: 25204541
An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms.
Breccia M, Voso MT, Aloe Spiriti MA, Fenu S, Maurillo L, Buccisano F, Tafuri A, Alimena G. Breccia M, et al. Among authors: fenu s. Ann Hematol. 2015 May;94(5):771-7. doi: 10.1007/s00277-015-2341-z. Epub 2015 Mar 7. Ann Hematol. 2015. PMID: 25743685 Review.
Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.
Musto P, Maurillo L, Simeon V, Poloni A, Finelli C, Balleari E, Ricco A, Rivellini F, Cortelezzi A, Tarantini G, Villani O, Mansueto G, Milella MR, Scapicchio D, Marziano G, Breccia M, Niscola P, Sanna A, Clissa C, Voso MT, Fenu S, Venditti A, Santini V, Angelucci E, Levis A. Musto P, et al. Among authors: fenu s. Br J Haematol. 2017 Jun;177(5):741-750. doi: 10.1111/bjh.14621. Epub 2017 Apr 17. Br J Haematol. 2017. PMID: 28419408 Free article.
Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS).
Fabiani E, Calabrese C, Niscola P, Balleari E, Molteni A, Finelli C, Falconi G, Fenu S, Fianchi L, Criscuolo M, Salvi F, Lavorgna S, Buccisano F, Maurillo L, Lo Coco F, Cilloni D, Voso MT. Fabiani E, et al. Among authors: fenu s. Br J Haematol. 2019 Jun;185(5):954-957. doi: 10.1111/bjh.15655. Epub 2018 Nov 8. Br J Haematol. 2019. PMID: 30407614 Free article. No abstract available.
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S. Angelucci E, et al. Among authors: fenu s. Eur J Haematol. 2014 Jun;92(6):527-36. doi: 10.1111/ejh.12300. Epub 2014 Apr 10. Eur J Haematol. 2014. PMID: 24580147 Clinical Trial.
SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience.
Mossuto S, Attardi E, Alesiani F, Angelucci E, Balleari E, Bernardi M, Binotto G, Bosi C, Calvisi A, Capodanno I, Carbone A, Castelli A, Cerrano M, Ciancia R, Cilloni D, Clavio M, Clissa C, Crisà E, Crugnola M, Della Porta MG, Di Renzo N, Di Veroli A, Fattizzo R, Fava C, Fenu S, Ferrara IL, Fianchi L, Filì C, Finelli C, Giai V, Frattini F, Gaidano V, Guaragna G, Gumenyuk S, Latagliata R, Mancini S, Messa E, Molteni A, Musto P, Niscola P, Oliva E, Palumbo GA, Pelizzari A, Pilo F, Poloni A, Riva M, Rivellini F, Sarlo C, Sciumé M, Secchi R, Selleri C, Tafuri A, Santini V. Mossuto S, et al. Among authors: fenu s. Hemasphere. 2020 Sep 23;4(5):e483. doi: 10.1097/HS9.0000000000000483. eCollection 2020 Oct. Hemasphere. 2020. PMID: 33062948 Free PMC article. No abstract available.
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study.
Buccisano F, Piccioni AL, Nobile C, Criscuolo M, Niscola P, Tatarelli C, Fianchi L, Villivà N, Neri B, Carmosino I, Gumenyuk S, Mancini S, Voso MT, Maurillo L, Breccia M, Zini G, Venditti A, Fenu S, Spiriti MA, Latagliata R; GROM (Gruppo Romano Mielodisplasie). Buccisano F, et al. Among authors: fenu s. Ann Hematol. 2016 Jun;95(7):1059-65. doi: 10.1007/s00277-016-2667-1. Epub 2016 Apr 19. Ann Hematol. 2016. PMID: 27091349
Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
Maurillo L, Breccia M, Buccisano F, Voso MT, Niscola P, Trapè G, Tatarelli C, D'Addosio A, Latagliata R, Fenu S, Piccioni AL, Fragasso A, Aloe Spiriti MA, Refrigeri M, Criscuolo M, Musto P, Venditti A. Maurillo L, et al. Among authors: fenu s. Eur J Haematol. 2015 Jul;95(1):52-6. doi: 10.1111/ejh.12476. Epub 2015 Mar 12. Eur J Haematol. 2015. PMID: 25764148
163 results